Resona Asset Management Co. Ltd. Raises Stake in Stryker Corporation $SYK

Resona Asset Management Co. Ltd. lifted its stake in shares of Stryker Corporation (NYSE:SYK) by 2.4% during the first quarter, HoldingsChannel.com reports. The firm owned 105,075 shares of the medical technology company’s stock after purchasing an additional 2,482 shares during the period. Resona Asset Management Co. Ltd.’s holdings in Stryker were worth $34,478,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Sankala Group LLC purchased a new stake in Stryker during the fourth quarter worth about $26,000. Godfrey Financial Associates Inc. purchased a new position in Stryker in the fourth quarter valued at about $26,000. United Financial Planning Group LLC purchased a new position in Stryker in the third quarter valued at about $27,000. Atlas Capital Advisors Inc. acquired a new stake in shares of Stryker during the 4th quarter valued at approximately $27,000. Finally, DJE Kapital AG purchased a new stake in shares of Stryker during the 4th quarter worth approximately $28,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Activity

In related news, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the transaction, the vice president owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP M Kathryn Fink sold 5,220 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the transaction, the vice president directly owned 13,137 shares in the company, valued at $3,728,937.45. The trade was a 28.44% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 323,264 shares of company stock valued at $100,659,489 over the last 90 days. Insiders own 4.60% of the company’s stock.

Stryker Trading Down 0.8%

Shares of Stryker stock opened at $327.17 on Thursday. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $404.87. The company has a market capitalization of $125.42 billion, a P/E ratio of 37.87, a P/E/G ratio of 2.11 and a beta of 0.77. The business has a 50 day moving average price of $309.71 and a 200 day moving average price of $338.22.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. During the same quarter in the prior year, the business posted $2.84 EPS. The company’s revenue for the quarter was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Sell-side analysts anticipate that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s payout ratio is 40.74%.

Wall Street Analyst Weigh In

SYK has been the topic of a number of research reports. Sanford C. Bernstein set a $410.00 price target on Stryker in a report on Friday, May 1st. Canaccord Genuity Group reduced their price objective on Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a report on Friday, May 1st. BMO Capital Markets assumed coverage on Stryker in a research report on Wednesday. They set an “outperform” rating and a $369.00 target price on the stock. BTIG Research lowered their target price on Stryker from $397.00 to $379.00 and set a “buy” rating on the stock in a report on Friday, May 1st. Finally, Weiss Ratings cut Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 4th. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $393.91.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.